Retatrutide is an investigational triple-receptor agonist that targets GLP-1, GIP and glucagon receptors. It is currently being researched for its potential effects on appetite regulation, body weight, glucose control, energy expenditure and overall metabolic function.

Contents: 5mg Retatrutide per vial.

Research has primarily focused on obesity and metabolic conditions, with clinical trials investigating its effects on weight reduction and related metabolic markers.